A Phase 4 interventional study of Metformin and Recommendations for lifestyle modification. in Atrial Fibrillation, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by University of Michigan · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Atrial Fibrillation by University of Michigan — 2 open to participants now, 3 under way, none of them phase 3. Atrial Fibrillation · University of Michigan.
Among the 10 studies in Atrial Fibrillation by University of Michigan, this one is the only one that started in 2021, is one of 3 in phase 4, and was the 7th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →2 of the 10 studies in Atrial Fibrillation by University of Michigan are open now, in 1 country. Recruiting first, the newest first:
University of Michigan · Sites in United States
Ages 18–79
University of Michigan
Ages 80+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 4 3
First in 2002; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 124 across the 8 interventional studies, 98 across the 2 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Michigan is the lead sponsor of 1,509 studies on the registry; 194 are open to participants now.
Of its 170 completed or terminated interventional studies of FDA-regulated products, 134 (79%) have results posted.
2 of the studies in Atrial Fibrillation by University of Michigan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03793465University of MichiganPilot-Tart Cherry, Mitral Transcriptome, and POAF Incidence | 2027-01 |
| NCT05991700University of MichiganAnthocyanin-Rich Table Grape Powder for Prophylaxis of Post-Operative Atrial Fibrillation | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Atrial Fibrillation by University of Michigan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial is being done to determine if metformin, a drug which is normally used in diabetes, can reduce atrial fibrillation in patients who are having an ablation for atrial fibrillation (AF). Atrial fibrillation is an abnormal heart rhythm which research has shown is related in part to obesity and diabetes.
It is anticipated that the participants treated in the metformin arm will have greater freedom from recurrent atrial arrhythmias after ablation.
Eligible participants enrolled in the trial will be assigned to one of the treatment arms (no treatment or metformin) and have follow-up visits up to approximately 1 year after the ablation. Additionally, all patients will also receive education on lifestyle changes and exercise which are standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard of care ablation with recommendations for lifestyle modification and metformin.
Drug: Metformin · Behavioral: Recommendations for lifestyle modification. · Device: AliveCor
Standard of care ablation with recommendations for lifestyle modification.
Behavioral: Recommendations for lifestyle modification. · Device: AliveCor
Metformin immediate release will be initiated at 250 milligrams (mg) daily (orally), and increased as tolerated to 2000 mg daily over a four week period. If a patient is unable to tolerate a dose increase they will return to their last tolerated dose after omitting one days dosing. 0 to Six weeks after the initiation of drug the patient will undergo (standard of care) ablation with the intent of achieving rhythm control. Participants will stay on the metformin 12 months after the ablation. In addition, all participants will receive education on lifestyle changes and exercise which are standard of care as well as have a discussion with their treating electrophysiologist and receive a handout.
Also known as: Glucophage
All subjects will receive education on lifestyle changes and exercise which are standard of care. This will include discussion with their treating electrophysiologist and a handout.
Device will be used in order to record an electrocardiogram during symptoms perceived to be AF. All patients will be instructed to transmit at least once per week.
Freedom From Recurrent Atrial Arrhythmias Between 3 to 12 Months After a Single Ablation to Eliminate Atrial Fibrillation (AF)
Results reflect participants who did not experience a recurrent atrial arrhythmia between 3 to 12 months after receiving an ablation. There was a 3-month blanking period after ablation during which recurrent atrial arrhythmias did not contribute to the primary endpoint's results.
Time frame: 12 months after ablation
Median Time to Recurrence of Atrial Fibrillation After a 3 Month Blanking Period of Ablation
Results reflect the median time in days for the recurrence of atrial fibrillation 3 months after ablation.
Time frame: up to 1 year after ablation
Freedom From Recurrent Atrial Arrhythmias at 6 Months After Ablation After the Blanking Period of 3 Months
Results reflect participants who did not experience a recurrent atrial arrhythmia between 3 to 6 months after receiving an ablation. There was a 3-month blanking period after ablation during which recurrent atrial arrhythmias did not contribute to the secondary endpoint's results.
Time frame: 3 to 6 months after ablation
Freedom From Recurrent Atrial Arrhythmias at 6 Months After Repeat Ablation
Results reflect participants who did not experience a recurrent atrial arrhythmia between 3 to 6 months after receiving a repeat ablation. There was a 3-month blanking period after ablation during which recurrent atrial arrhythmias did not contribute to the secondary endpoint's results.
Time frame: 6 months after a repeated ablation
Atrial Fibrillation Severity Score (AFSS) - Part C
There were a total of 7 questions in this questionnaire. This collected information regarding the participants atrial fibrillation for subjects to report severity of symptoms (i.e. palpitations, shortness of breath at rest/physical activity, exercise intolerance, fatigue at rest, and lightheadedness/dizziness, chest pain or pressure) on a Likert scale from 0 (subject did not have this symptom) to 5 (symptom bothers subject a great deal). The total range of the scale was 0 to 35, with 0 meaning no symptoms and 35 meaning maximum number of symptoms.
Time frame: 12 months after ablation
Change in Weight at 3 Months After Ablation
Results reflect change in weight from baseline 3 months after ablation.
Time frame: Baseline and 3 months after ablation
Change in Weight at 6 Months After Ablation
Results reflect change in weight from baseline 6 months after ablation.
Time frame: Baseline and 6-months after ablation
Change in Hemoglobin A1c at 6 Months After Ablation
Results reflect change in A1c from baseline 6 months after ablation.
Time frame: Baseline and 6-months after ablation
Change in Hemoglobin A1C at 12 Months After Ablation
Results reflect change in A1c from baseline 12 months after ablation.
Time frame: Baseline and 12-months after ablation
Number of Participants With Major Procedural Complication up to 30 Days Post-Ablation
Results reflect number of participants who experienced a major procedural complication following ablation. Complications included but were not limited to major bleeding, vascular injury, myocardial perforation, stroke, and mortality.
Time frame: up to 30 days
Atrial Fibrillation Related Morbidity During Follow-up
During follow-up visits information was collected regarding Emergency department visits and hospital admissions due to Atrial Fibrillation, Transient Ischemic Attack (TIA)/cerebrovascular accident (CVA), and mortality. These were collected as total number of participants who experienced one of these events.
Time frame: up to approximately 1 year after ablation
Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices
Results reflect the percentage of days during which some form of electrocardiographic monitoring demonstrated atrial fibrillation.
Time frame: 3 months after ablation
Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices, EKGs, Event Monitoring, Cardiac Implantable Electronic Devices
Results reflect the percentage of days during which some form of electrocardiographic monitoring demonstrated atrial fibrillation.
Time frame: 6 months after ablation
Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices
Results reflect the percentage of days during which some form of electrocardiographic monitoring demonstrated atrial fibrillation.
Time frame: 1 year after ablation
| Milestone | Metformin | Standard of Care |
|---|---|---|
| Started | 49 | 50 |
| Completed | 49 | 50 |
| Not completed | 0 | 0 |
Results reflect participants who did not experience a recurrent atrial arrhythmia between 3 to 12 months after receiving an ablation. There was a 3-month blanking period after ablation during which recurrent atrial arrhythmias did not contribute to the primary endpoint's results.
| Participants | Metformin | Standard of Care |
|---|---|---|
| Freedom From Recurrent Atrial Arrhythmias Between 3 to 12 Months After a Single Ablation to Eliminate Atrial Fibrillation (AF) | 38 | 29 |
Results reflect the median time in days for the recurrence of atrial fibrillation 3 months after ablation.
| Days | Metformin | Standard of Care |
|---|---|---|
| Median Time to Recurrence of Atrial Fibrillation After a 3 Month Blanking Period of Ablation | NA (NA to NA) | NA (NA to NA) |
Results reflect participants who did not experience a recurrent atrial arrhythmia between 3 to 6 months after receiving an ablation. There was a 3-month blanking period after ablation during which recurrent atrial arrhythmias did not contribute to the secondary endpoint's results.
| Participants | Metformin | Standard of Care |
|---|---|---|
| Freedom From Recurrent Atrial Arrhythmias at 6 Months After Ablation After the Blanking Period of 3 Months | 42 | 40 |
Results reflect participants who did not experience a recurrent atrial arrhythmia between 3 to 6 months after receiving a repeat ablation. There was a 3-month blanking period after ablation during which recurrent atrial arrhythmias did not contribute to the secondary endpoint's results.
| Participants | Metformin | Standard of Care |
|---|---|---|
| Freedom From Recurrent Atrial Arrhythmias at 6 Months After Repeat Ablation | 2 | 4 |
There were a total of 7 questions in this questionnaire. This collected information regarding the participants atrial fibrillation for subjects to report severity of symptoms (i.e. palpitations, shortness of breath at rest/physical activity, exercise intolerance, fatigue at rest, and lightheadedness/dizziness, chest pain or pressure) on a Likert scale from 0 (subject did not have this symptom) to 5 (symptom bothers subject a great deal). The total range of the scale was 0 to 35, with 0 meaning no symptoms and 35 meaning maximum number of symptoms.
| score on a scale | Metformin | Standard of Care |
|---|---|---|
| Atrial Fibrillation Severity Score (AFSS) - Part C | 2.7 ± 6.1 | 5 ± 8 |
Results reflect change in weight from baseline 3 months after ablation.
| Kilograms | Metformin | Standard of Care |
|---|---|---|
| Change in Weight at 3 Months After Ablation | -5.1 ± 4.1 | -7 ± 3.1 |
Results reflect change in weight from baseline 6 months after ablation.
| Kilograms | Metformin | Standard of Care |
|---|---|---|
| Change in Weight at 6 Months After Ablation | 0.4 ± 4.8 | 0.3 ± 3.2 |
Results reflect change in A1c from baseline 6 months after ablation.
| percentage of glycated hemoglobin | Metformin | Standard of Care |
|---|---|---|
| Change in Hemoglobin A1c at 6 Months After Ablation | 0.09 ± 0.3 | 0.06 ± 0.3 |
Results reflect change in A1c from baseline 12 months after ablation.
| percentage of glycated hemoglobin | Metformin | Standard of Care |
|---|---|---|
| Change in Hemoglobin A1C at 12 Months After Ablation | 5.6 ± 1.2 | 5.7 ± 0.4 |
Results reflect number of participants who experienced a major procedural complication following ablation. Complications included but were not limited to major bleeding, vascular injury, myocardial perforation, stroke, and mortality.
| Participants | Metformin | Standard of Care |
|---|---|---|
| Number of Participants With Major Procedural Complication up to 30 Days Post-Ablation | 0 | 0 |
During follow-up visits information was collected regarding Emergency department visits and hospital admissions due to Atrial Fibrillation, Transient Ischemic Attack (TIA)/cerebrovascular accident (CVA), and mortality. These were collected as total number of participants who experienced one of these events.
| Participants | Metformin | Standard of Care |
|---|---|---|
| Atrial Fibrillation Related Morbidity During Follow-up | 5 | 3 |
Results reflect the percentage of days during which some form of electrocardiographic monitoring demonstrated atrial fibrillation.
| Percentage of Days | Metformin | Standard of Care |
|---|---|---|
| Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices | 0 (0 to 14) | 0 (0 to 28) |
Results reflect the percentage of days during which some form of electrocardiographic monitoring demonstrated atrial fibrillation.
| Percentage of Days | Metformin | Standard of Care |
|---|---|---|
| Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices, EKGs, Event Monitoring, Cardiac Implantable Electronic Devices | 0 (0 to 0) | 0 (0 to 18) |
Results reflect the percentage of days during which some form of electrocardiographic monitoring demonstrated atrial fibrillation.
| Percentage of Days | Metformin | Standard of Care |
|---|---|---|
| Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices | 0 (0 to 0) | 0 (0 to 25) |
Collected over 13 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metformin | 0/49 (0%) | 5/49 (10.2%) | 12/49 (24.5%) |
| Standard of Care | 0/50 (0%) | 3/50 (6%) | 0/50 (0%) |
| Event | Metformin | Standard of Care |
|---|---|---|
| Atrial fibrillation (hospital admission)Cardiac disorders | 5/49 | 3/50 |
| Event | Metformin | Standard of Care |
|---|---|---|
| Gastrointestinal intolerance (diarrhea/nausea)Gastrointestinal disorders | 12/49 | 0/50 |
| Age, Continuous(years) | Metformin | Standard of Care | Total |
|---|---|---|---|
| Mean | 62 ± 8.2 | 63.2 ± 10.5 | 63 ± 9.5 |
| Sex: Female, Male(Participants) | Metformin | Standard of Care | Total |
|---|---|---|---|
| Female | 12 | 18 | 30 |
| Male | 37 | 32 | 69 |
| Ethnicity (NIH/OMB)(Participants) | Metformin | Standard of Care | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 45 | 46 | 91 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Race (NIH/OMB)(Participants) | Metformin | Standard of Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 41 | 48 | 89 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 5 | 2 | 7 |
| Region of Enrollment(Participants) | Metformin | Standard of Care | Total |
|---|---|---|---|
| United States | 49 | 50 | 99 |
| Type of Atrial Fibrillation (Paroxysmal vs. Persistent)(Participants) | Metformin | Standard of Care | Total |
|---|---|---|---|
| Paroxysmal (≤7 days) | 24 | 22 | 46 |
| Persistent (≥8 days) | 25 | 28 | 53 |
| History of Prior Ablation(Participants) | Metformin | Standard of Care | Total |
|---|---|---|---|
| Count of participants | 13 | 9 | 22 |
| Weight(kilograms) | Metformin | Standard of Care | Total |
|---|---|---|---|
| Mean | 102.8 ± 17.7 | 104.0 ± 21.2 | 103.4 ± 19.5 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2021 to primary completion in Jul 2025, 53 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 53 months is close to that.
Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin